ATE339406T1 - Chinazoline verbindungen als heilmittel - Google Patents
Chinazoline verbindungen als heilmittelInfo
- Publication number
- ATE339406T1 ATE339406T1 AT00958907T AT00958907T ATE339406T1 AT E339406 T1 ATE339406 T1 AT E339406T1 AT 00958907 T AT00958907 T AT 00958907T AT 00958907 T AT00958907 T AT 00958907T AT E339406 T1 ATE339406 T1 AT E339406T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- chinazoline
- remedies
- formulaand
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15562399P | 1999-09-23 | 1999-09-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE339406T1 true ATE339406T1 (de) | 2006-10-15 |
Family
ID=22556162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00958907T ATE339406T1 (de) | 1999-09-23 | 2000-09-18 | Chinazoline verbindungen als heilmittel |
Country Status (8)
Country | Link |
---|---|
US (1) | US6399603B1 (de) |
EP (1) | EP1218358B1 (de) |
JP (1) | JP2003509501A (de) |
AT (1) | ATE339406T1 (de) |
AU (1) | AU7031500A (de) |
DE (1) | DE60030741T2 (de) |
ES (1) | ES2270867T3 (de) |
WO (1) | WO2001021598A1 (de) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1088821A1 (de) * | 1999-09-28 | 2001-04-04 | Applied Research Systems ARS Holding N.V. | Pharmazeutisch wirksamer Sulfonamid Derivate |
EP1257536A1 (de) | 2000-01-27 | 2002-11-20 | Cytovia, Inc. | Substituierte nicotinamiden und analoge als caspaseaktivatoren und apoptose-induzierende mittel und ihre verwendung |
US7229986B2 (en) * | 2000-05-16 | 2007-06-12 | Takeda Pharmaceutical Company Ltd. | Melanin-concentrating hormone antagonist |
YU23503A (sh) * | 2000-09-29 | 2006-03-03 | Neurogen Corporation | Mali molekuli kao modulatori receptora c5a visokog afiniteta |
WO2002079459A2 (en) * | 2001-03-29 | 2002-10-10 | Nsgene A/S | Means for inhibiting proteolytical processing of parkin |
AT413485B (de) * | 2001-04-09 | 2006-03-15 | Hemoteq Gmbh | Mit einem pharmazeutikum beschichteter stent |
WO2002087577A1 (fr) * | 2001-04-26 | 2002-11-07 | Nippon Shinyaku Co., Ltd. | Produits pharmaceutiques |
EP1430032A2 (de) * | 2001-09-24 | 2004-06-23 | Elan Pharmaceuticals, Inc. | Substituierte amide für die behandlung von neurologischen erkrankungen |
AU2002361846A1 (en) * | 2001-12-21 | 2003-07-15 | Bayer Pharmaceuticals Corporation | Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
DE60329910D1 (de) * | 2002-03-29 | 2009-12-17 | Novartis Vaccines & Diagnostic | Substituierte benzazole und ihre verwendung als raf-kinase-hemmer |
US8299108B2 (en) * | 2002-03-29 | 2012-10-30 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of raf kinase |
EP1398032A1 (de) * | 2002-09-10 | 2004-03-17 | PheneX Pharmaceuticals AG | 4-Oxochinazoline, die an den LXR Kernrezeptor binden |
US7893096B2 (en) * | 2003-03-28 | 2011-02-22 | Novartis Vaccines And Diagnostics, Inc. | Use of small molecule compounds for immunopotentiation |
WO2004111014A1 (en) * | 2003-06-06 | 2004-12-23 | Vertex Pharmaceuticals Incorporated | Pyrimidine derivatives as modulators of atp-binding cassette transporters |
WO2005013914A2 (en) | 2003-08-08 | 2005-02-17 | Vertex Pharmaceuticals Incorporated | Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain |
US20050124562A1 (en) * | 2003-09-23 | 2005-06-09 | Joseph Guiles | Bis-quinazoline compounds for the treatment of bacterial infections |
EP1682126B1 (de) * | 2003-10-16 | 2009-07-01 | Novartis Vaccines and Diagnostics, Inc. | Substituierte benzazole und ihre verwendung als raf-kinase-hemmer |
DE602006010665D1 (en) | 2005-02-07 | 2010-01-07 | Hoffmann La Roche | Heterocyclsche substituierte phenylmethanone als inhibitoren des glycintransporters 1 |
EP2004619A1 (de) | 2006-03-23 | 2008-12-24 | Amgen Inc. | Heterocyclische 1-phenylsulfonyl-diaza-amidverbindungen und ihre verwendung als modulatoren von hydroxsteroid-dehydrogenasen |
CN101687821A (zh) * | 2007-06-21 | 2010-03-31 | Irm责任有限公司 | 蛋白激酶抑制剂及其使用方法 |
EP2226315A4 (de) | 2007-12-28 | 2012-01-25 | Carna Biosciences Inc | 2-aminochinazolin-derivat |
JP5370957B2 (ja) * | 2008-08-20 | 2013-12-18 | 学校法人日本大学 | アポトーシス抑制剤 |
US20100267752A1 (en) * | 2008-10-15 | 2010-10-21 | Gilead Palo Alto, Inc. | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS |
SG178552A1 (en) | 2009-08-26 | 2012-03-29 | Cylene Pharmaceuticals Inc | Condensed quinolines as protein kinase modulators |
US9051296B2 (en) | 2009-11-16 | 2015-06-09 | Raqualia Pharma Inc. | Aryl carboxamide derivatives as TTX-S blockers |
CN101919833B (zh) * | 2010-07-16 | 2012-01-11 | 暨南大学 | 一种芳香类化合物作为制备Caspase 3抑制剂的用途 |
MX2015005744A (es) * | 2012-11-09 | 2016-02-10 | Univ Cornell | Inhibidores de malti de molecula pequeña. |
US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
HUE043465T2 (hu) * | 2013-08-23 | 2019-08-28 | Neupharma Inc | Kémiai anyagok, készítmények és módszerek |
UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
MX2017008520A (es) | 2014-12-24 | 2018-03-01 | Gilead Sciences Inc | Compuestos de pirimidina fusionada para el tratamiento del virus de inmunodeficiencia humana (vih). |
TW202237569A (zh) * | 2014-12-24 | 2022-10-01 | 美商基利科學股份有限公司 | 喹唑啉化合物 |
JP6356919B2 (ja) * | 2014-12-24 | 2018-07-11 | ギリアード サイエンシーズ, インコーポレイテッド | Hivの処置のためのイソキノリン化合物 |
AU2016220219B2 (en) | 2015-02-17 | 2020-05-14 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
KR102087918B1 (ko) | 2015-03-24 | 2020-03-12 | 상하이 잉리 파마슈티컬 컴퍼니 리미티드 | 융합 고리 유도체, 이의 제조방법, 중간체, 약물 조성물 및 응용 |
CN111440189B (zh) * | 2015-04-24 | 2022-08-09 | 广州再极医药科技有限公司 | 稠环嘧啶氨基衍生物、其制备方法、中间体、药物组合物及应用 |
EP3354653B1 (de) * | 2015-07-21 | 2019-09-04 | Guangzhou Maxinovel Pharmaceuticals Co. Ltd. | Kondensierte ringpyrimidinverbindung, zwischenprodukt und herstellungsverfahren, zusammensetzung und verwendung davon |
WO2017103932A1 (en) | 2015-12-17 | 2017-06-22 | Biokine Therapeutics Ltd. | Small molecules for inhibiting chemokine activity, a kinase activity and/or cancer cells growth |
EP3390378B1 (de) | 2015-12-17 | 2022-03-30 | AlonBio Ltd. | Kleine moleküle gegen krebs |
AU2017312561B2 (en) | 2016-08-15 | 2022-06-30 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
CN114096524A (zh) | 2019-05-15 | 2022-02-25 | 阿龙拜欧有限公司 | 用于治疗癌症、抑制趋化因子活性和/或诱导细胞死亡的小分子 |
WO2021175155A1 (zh) * | 2020-03-06 | 2021-09-10 | 广州再极医药科技有限公司 | 噻吩并嘧啶类衍生物及其制备方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2488379A (en) * | 1949-11-15 | Quinazoline derivatives | ||
GB585363A (en) * | 1944-08-31 | 1947-02-05 | Erancis Henry Swinden Curd | New heterocyclic compounds |
US4079057A (en) * | 1977-05-31 | 1978-03-14 | Bristol-Myers Company | Selective immunosuppressive agents |
DD225131A1 (de) * | 1984-01-30 | 1985-07-24 | Akad Wissenschaften Ddr | Verfahren zur herstellung 2-substituierter 3,4-dihydrochinazolin-4-one |
TW334434B (en) * | 1995-05-16 | 1998-06-21 | Kanebo Ltd | Novel quinazoline compound and anti-tumor agent |
WO2000015645A1 (fr) * | 1998-09-11 | 2000-03-23 | Kyorin Pharmaceutical Co., Ltd. | Derives d'esters phosphoniques et leur procede de production |
AU5648699A (en) * | 1998-09-11 | 2000-04-03 | Kyorin Pharmaceutical Co. Ltd. | Malonic diester derivatives and process for producing the same |
-
2000
- 2000-09-18 ES ES00958907T patent/ES2270867T3/es not_active Expired - Lifetime
- 2000-09-18 JP JP2001524977A patent/JP2003509501A/ja active Pending
- 2000-09-18 DE DE60030741T patent/DE60030741T2/de not_active Expired - Lifetime
- 2000-09-18 AU AU70315/00A patent/AU7031500A/en not_active Abandoned
- 2000-09-18 WO PCT/GB2000/003555 patent/WO2001021598A1/en active IP Right Grant
- 2000-09-18 EP EP00958907A patent/EP1218358B1/de not_active Expired - Lifetime
- 2000-09-18 AT AT00958907T patent/ATE339406T1/de not_active IP Right Cessation
- 2000-09-22 US US09/668,322 patent/US6399603B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU7031500A (en) | 2001-04-24 |
US6399603B1 (en) | 2002-06-04 |
DE60030741D1 (de) | 2006-10-26 |
EP1218358A1 (de) | 2002-07-03 |
DE60030741T2 (de) | 2007-09-06 |
ES2270867T3 (es) | 2007-04-16 |
WO2001021598A1 (en) | 2001-03-29 |
JP2003509501A (ja) | 2003-03-11 |
EP1218358B1 (de) | 2006-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE339406T1 (de) | Chinazoline verbindungen als heilmittel | |
DE60038183D1 (de) | Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe | |
ATE329897T1 (de) | Verbindungen und zusammensetzungen zur verabreichung aktiven substanzen | |
DK1200412T3 (da) | Antiproliferative imidazolforbindelser | |
DE60034240D1 (de) | Drogen zur behandlung maligner tumoren | |
BR9711986A (pt) | Compostos farmac-uticos | |
ATE355288T1 (de) | Verbindungen und therapeutische methoden | |
DE60105025D1 (de) | Pharmazeutische verbindungen zur behandlung von chronisch-obstruktiver bronchopneumonie | |
DE69729183T2 (de) | Als entzündungshemmende mittel nützliche dihydrobenzofurane und verwandte verbindungen | |
GB9907571D0 (en) | Compounds | |
SG162614A1 (en) | Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors | |
SE0003476D0 (sv) | Compounds | |
DE60026491D1 (de) | Melagatran zur behandlung von entzündungen | |
AU2001246999A1 (en) | New neurokinin antagonists for use as medicaments | |
ES2194129T3 (es) | Compuestos farmaceuticos. | |
SE0004827D0 (sv) | Therapeutic compounds | |
DE60114597D1 (de) | Naphthamid-neurokinin antagonisten zur verwendung als medikamente | |
NO20014889D0 (no) | Fremgangsmåte for fremstilling av medisinske midler | |
PT1551850E (pt) | 2 oxo-voruscharina e seus derivados | |
ITTO20001109A0 (it) | Composizione farmaceutica per il trattamento anti m. ulcerans. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |